<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02816567</url>
  </required_header>
  <id_info>
    <org_study_id>PA16045</org_study_id>
    <nct_id>NCT02816567</nct_id>
  </id_info>
  <brief_title>Laparoscopic Surgery and Abdominal Compliance</brief_title>
  <acronym>COELIOCUR</acronym>
  <official_title>Laparoscopic Surgery and Abdominal Compliance Factors Including Neuromuscular Blocking Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <brief_summary>
    <textblock>
      The objective of the study is to describe factors influencing abdominal compliance during&#xD;
      laparoscopic surgery, including neuromuscular blocking agents (NMBA). The use of NMBA is&#xD;
      randomized and blinded from the surgeons and the anesthesiologist. The abdominal compliance&#xD;
      is measured by pressure/volume relationship.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and rationale. Abdominal laparoscopic surgery is widely used. The meet good&#xD;
      conditions, the surgeons need a large enough workspace. Carbonic gaz is insufflated in the&#xD;
      intraperitoneal space but limited by the induced pressure which usually must not be above&#xD;
      15mm mercury (Hg) because of subsequent organ failures. The relationship between pressure and&#xD;
      gaz volume insufflated defines the abdominal compliance (ΔV/ΔP).&#xD;
&#xD;
      The use of neuromuscular blocking agents (NMBA) is often used during abdominal laparoscopic&#xD;
      surgery in order to reduce abdominal tonus, create a sufficient laparoscopic workspace hence&#xD;
      improving abdominal compliance. However, considering good working conditions could be&#xD;
      achieved by the use of NMBA, other factors could be considered like body weight, length, BMI,&#xD;
      surgical abdominal history, parity.&#xD;
&#xD;
      Main objective : To compare the working surgical conditions and the pneumoperitoinea volume&#xD;
      obtained during abdominal laparoscopic surgery with and without initial NMBA use.&#xD;
&#xD;
      Hypothesis: The use of NMBA improve the incidence of good surgical working conditions.&#xD;
&#xD;
      Study Design : Randomized blinded clinical trial. Two patients groups are compared, one&#xD;
      receiving NMBA and one receiving a placebo. Randomisation will be realised by 1/1 ratio in&#xD;
      blocks of 4.&#xD;
&#xD;
      The primary outcome is a composite criteria : the obtention of laparoscopic workspace greater&#xD;
      than 3 liters associated with an abdominal pressure lesser than 15mmHg and a good surgical&#xD;
      rating scale.&#xD;
&#xD;
      A statistical analysis reveal that 90 patients in each group need to be included from&#xD;
      estimated 90% satisfying surgical conditions in NMBA group and 70% in placebo group.&#xD;
&#xD;
      In the placebo group, when surgical conditions are not correct (insufflated volume lesser&#xD;
      than 3 liters or surgeon dissatisfaction), NMBA are used. This define the secondary use of&#xD;
      NMBA.&#xD;
&#xD;
      Methods :&#xD;
&#xD;
      Anesthesia will be induced in all patients by target controlled infusions of propofol and&#xD;
      sufentanil respectively with initial targets of 6 microgram/ml and 0,4 ng/ml.&#xD;
&#xD;
      The initial NMBA bolus in the NMBA group is 0,15 mg/kg of cisatracurium. A similar volume of&#xD;
      isotonic saline serum is used in the placebo group.&#xD;
&#xD;
      The abdomen is inflated to 5, 10 and 15 mmHg and volumes at each pressure level are measured&#xD;
      in order to evaluate the abdominal compliance.&#xD;
&#xD;
      After those measures, the anesthesiologist is unblinded of NMBA use. If the workspace volume&#xD;
      is lesser than 3 liters, or, in case of surgeon dissatisfaction (using the surgical rating&#xD;
      scale), NMBA can be used, defining secondary NMBA used.&#xD;
&#xD;
      Anesthesia is maintained by continous infusions of propofol and sufentanil aiming BIS target&#xD;
      of 40 to 60.&#xD;
&#xD;
      When used, curarisation is maintained by a continuous infusion of cisatracurium (0,06 to 0,12&#xD;
      mg/kg/h) targetting 0 or 1 TOF response.&#xD;
&#xD;
      Safety issues : During anesthesia induction, if ventilation or tracheal intubation&#xD;
      difficulties were to happen, the anesthesiologist is unblinded and any anesthesia protocol&#xD;
      can be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of pneumoperiteum laparoscopic workspace</measure>
    <time_frame>Day 0 (after anesthesia induction)</time_frame>
    <description>laparoscopic workspace assessed by volume of pneumoperiteum &gt; 3 Liters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>score SRS (Surgical Rating Scale)</measure>
    <time_frame>Day 0 (after anesthesia induction)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Patients Ongoing Elective Abdominal Laparoscopy</condition>
  <arm_group>
    <arm_group_label>NMBA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <arm_group_label>NMBA group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NMBA - cisatracurium</intervention_name>
    <arm_group_label>NMBA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo - isotonic saline serum</intervention_name>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <arm_group_label>NMBA group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic surgery</intervention_name>
    <arm_group_label>NMBA group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  elective abdominal laparoscopy (cholecystectomy, colectomy, gastric bypass, sleeve&#xD;
             gastrectomy, hepatic resection, splenectomy, hernial surgery, explorative laparoscopy)&#xD;
&#xD;
          -  &gt;18 yo&#xD;
&#xD;
          -  patients who accept the protocol and sign it&#xD;
&#xD;
          -  patients affiliated at the social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  formal indication of NMBA use (predictive difficult tracheal intubation, predictive&#xD;
             difficult facial ventilation)&#xD;
&#xD;
          -  patients who needs a crush induction&#xD;
&#xD;
          -  NMBA allergia&#xD;
&#xD;
          -  patients who present a contraindication to the propofol or sufentanil&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breastfeeding womens&#xD;
&#xD;
          -  patients protected by the law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Beny Charbit</last_name>
    <phone>326787029</phone>
    <phone_ext>33</phone_ext>
    <email>bcharbit@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>France</city>
        <state>Reims</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

